Literature DB >> 20332369

How I treat common variable immune deficiency.

Charlotte Cunningham-Rundles1.   

Abstract

Common variable immunodeficiency is a rare immune deficiency, characterized by low levels of serum immunoglobulin G, A, and/or M with loss of antibody production. The diagnosis is most commonly made in adults between the ages of 20 and 40 years, but both children and older adults can be found to have this immune defect. The range of clinical manifestations is broad, including acute and chronic infections, inflammatory and autoimmune disease, and an increased incidence of cancer and lymphoma. For all these reasons, the disease phenotype is both heterogeneous and complex. Contributing to the complexity is that patient cohorts are generally small, criteria used for diagnosis vary, and the doses of replacement immune globulin differ. In addition, routines for monitoring patients over the years and protocols for the use of other biologic agents for complications have not been clarified or standardized. In the past few years, data from large patient registries have revealed that both selected laboratory markers and clinical phenotyping may aid in dissecting groups of subjects into biologically relevant categories. This review presents my approach to the diagnosis and treatment of patients with common variable immunodeficiency, with suggestions for the use of laboratory biomarkers and means of monitoring patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332369      PMCID: PMC2904582          DOI: 10.1182/blood-2010-01-254417

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  100 in total

1.  Immune competence and switched memory B cells in common variable immunodeficiency.

Authors:  Jimmy Ko; Lin Radigan; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2005-07       Impact factor: 3.969

Review 2.  Subcutaneous administration of IgG.

Authors:  Melvin Berger
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

3.  CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency.

Authors:  Menno C van Zelm; Julie Smet; Brigitte Adams; Françoise Mascart; Liliane Schandené; Françoise Janssen; Alina Ferster; Chiung-Chi Kuo; Shoshana Levy; Jacques J M van Dongen; Mirjam van der Burg
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

4.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial.

Authors:  H W Eijkhout; J W van Der Meer; C G Kallenberg; R S Weening; J T van Dissel; L A Sanders; P F Strengers; H Nienhuis; P T Schellekens
Journal:  Ann Intern Med       Date:  2001-08-07       Impact factor: 25.391

Review 5.  Common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

6.  Graft-versus-host disease after liver and small bowel transplantation in a child.

Authors:  J Reyes; S Todo; M Green; E Yunis; D Schoner; S Kocoshis; H Furukawa; K Abu-Elmagd; A Tzakis; J Bueno; T E Starzl
Journal:  Clin Transplant       Date:  1997-10       Impact factor: 2.863

7.  Novel mutations in a Japanese patient with CD19 deficiency.

Authors:  H Kanegane; K Agematsu; T Futatani; M M Sira; K Suga; T Sekiguchi; M C van Zelm; T Miyawaki
Journal:  Genes Immun       Date:  2007-09-20       Impact factor: 2.676

8.  Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency--possible immunologic and clinical consequences.

Authors:  P Aukrust; E Lien; A K Kristoffersen; F Müller; C J Haug; T Espevik; S S Frøland
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

9.  Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects.

Authors:  B Piqueras; C Lavenu-Bombled; L Galicier; F Bergeron-van der Cruyssen; L Mouthon; S Chevret; P Debré; C Schmitt; E Oksenhendler
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

10.  Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency.

Authors:  Isabella Quinti; Annarosa Soresina; Giuseppe Spadaro; Silvana Martino; Simona Donnanno; Carlo Agostini; Pignata Claudio; Dammacco Franco; Anna Maria Pesce; Federica Borghese; Andrea Guerra; Roberto Rondelli; Alessandro Plebani
Journal:  J Clin Immunol       Date:  2007-02-14       Impact factor: 8.542

View more
  74 in total

1.  Immunological characteristics and two novel mutations in TACI in a cohort of 28 pediatric patients with common variable immunodeficiency.

Authors:  María B Almejún; Elisa Sajaroff; Miguel Galicchio; Matías Oleastro; Andrea Bernasconi; Marta Zelazko; Silvia Danielian
Journal:  J Clin Immunol       Date:  2011-11-11       Impact factor: 8.317

2.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

3.  Primary sclerosing cholangitis in common variable immune deficiency.

Authors:  Mahboobeh Mahdavinia; Mehdi Mirsaeidi; Faraz Bishehsari; Kris McGrath
Journal:  Allergol Int       Date:  2015-01-06       Impact factor: 5.836

4.  Parental consanguinity is associated with a severe phenotype in common variable immunodeficiency.

Authors:  Claire Rivoisy; Laurence Gérard; David Boutboul; Marion Malphettes; Claire Fieschi; Isabelle Durieu; François Tron; Agathe Masseau; Pierre Bordigoni; Laurent Alric; Julien Haroche; Cyrille Hoarau; Alice Bérézné; Maryvonnick Carmagnat; Gael Mouillot; Eric Oksenhendler
Journal:  J Clin Immunol       Date:  2011-10-15       Impact factor: 8.317

5.  CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters.

Authors:  L J Maarschalk-Ellerbroek; P A de Jong; J M van Montfrans; J W J Lammers; A C Bloem; A I M Hoepelman; P M Ellerbroek
Journal:  J Clin Immunol       Date:  2014-06-21       Impact factor: 8.317

6.  Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency.

Authors:  Timothy J Franxman; Laura E Howe; James R Baker
Journal:  J Clin Immunol       Date:  2014-07-27       Impact factor: 8.317

Review 7.  Human B cell defects in perspective.

Authors:  Charlotte Cunningham-Rundles
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 8.  Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature.

Authors:  Antonio Pecoraro; Liliana Nappi; Ludovica Crescenzi; Francesco P D'Armiento; Arturo Genovese; Giuseppe Spadaro
Journal:  J Clin Immunol       Date:  2017-11-14       Impact factor: 8.317

9.  Late-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry.

Authors:  Francesca Fioredda; Gioacchino Andrea Rotulo; Piero Farruggia; Francesca Dagliano; Marta Pillon; Angela Trizzino; Lucia Notarangelo; Laura Luti; Tiziana Lanza; Paola Terranova; Marina Lanciotti; Isabella Ceccherini; Alice Grossi; Laura Porretti; Federico Verzegnassi; Elena Mastrodicasa; Angelica Barone; Giovanna Russo; Sonia Bonanomi; Gianluca Boscarol; Andrea Finocchi; Marinella Veltroni; Ugo Ramenghi; Daniela Onofrillo; Baldassare Martire; Roberta Ghilardi; Paola Giordano; Saverio Ladogana; Nicoletta Marra; Sabrina Zanardi; Fabian Beier; Maurizio Miano; Carlo Dufour
Journal:  Blood Adv       Date:  2020-11-24

10.  Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.

Authors:  M Ponsford; E Carne; C Kingdon; C Joyce; C Price; C Williams; T El-Shanawany; P Williams; S Jolles
Journal:  Clin Exp Immunol       Date:  2015-09-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.